ClinicalTrials.gg
CompletedNCT04788641Updated Apr 5, 2024Results posted

Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects

A Phase 1 interventional study of Tacrolimus and Cyclosporin in Hyperkalaemia, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-05.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 39 studies in Hyperkalemia by AstraZeneca — 2 open to participants now, 3 under way, 1 of them phase 3. Hyperkalemia · AstraZeneca.

Enrollment
21st of 25
62 · median 150
Started
2021
with 8 others
Phase 1
2 of 39
none open now
Registered
25th of 39
by date

Among the 39 studies in Hyperkalemia by AstraZeneca, this one is the 21st largest by enrollment of the 25 interventional ones that give a count, is one of 9 that started in 2021, is one of 2 in phase 1, and was the 25th registered.

Hyperkalemia

134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.

Browse Hyperkalemia studies →

Open to participants now

2 of the 39 studies in Hyperkalemia by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Hyperkalemia by AstraZeneca, or all of them as a file.
02

Study summary

This study will be an open-label, randomised sequence, 2-period, 2-cohort, 2-treatment in each cohort, cross-over study in healthy subjects (males and females of non-childbearing potential), performed at a single study centre.

Read the detailed description

The study will comprise:

  • A screening period of maximum 28 days;
  • Two treatment periods:

    • Treatment Period 1 starts with admission to the Clinical Unit on Day -1, followed by dosing on Day 1 with the assigned treatment (A, B, C, or D) as per assigned cohort and treatment sequence, followed by a washout period of at least 14 days.
    • Treatment Period 2 starts with admission to Clinical Unit on Day -1, followed by dosing on Day 1 with cross-over treatment as per assigned cohort, followed by a follow-up period of 7 to 10 days.
  • A follow-up visit/early termination visit at 7 to 10 days after the last investigation medicinal product (IMP) administration.

Subjects will be assigned to either Cohort 1 (tacrolimus) or to Cohort 2 (cyclosporin). Each cohort will have 2 treatment periods. Subjects in each cohort will be randomly assigned to one of 2 treatment sequences (AB\|BA or CD\|DC) where,

  • Treatment A: Tacrolimus
  • Treatment B: Tacrolimus + SZC
  • Treatment C: Cyclosporin
  • Treatment D: Cyclosporin + SZC
03

Conditions studied

  • Hyperkalaemia

Browse trials for

Keywords

  • Pharmacokinetics
  • Sodium Zirconium Cyclosilicate
  • Tacrolimus
  • Cyclosporin
  • Drug-drug interaction study
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects aged 18 to 50 years (both inclusive)

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
  • History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important abnormalities in rhythm, conduction or morphology of the 12-lead safety (ECG), at screening visit and/or admission to the Clinical Unit.
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study.
  • History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to SZC, tacrolimus, or cyclosporin.
  • Subjects who have previously received SZC.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Subjects in Cohort 1 will be randomised in a 1:1 ratio to receive one of the 2 treatment sequences and then cross-over to the other: tacrolimus alone (treatment A) followed by the combination treatment of tacrolimus and SZC (treatment B) or vice versa.

    Drug: Tacrolimus · Drug: Sodium Zirconium Cyclosilicate

  • Experimental
    Cohort 2

    Subjects in Cohort 2 will be randomised in a 1:1 ratio to receive one of the 2 treatment sequences and then cross-over to the other: cyclosporin alone (treatment C) followed by the combination treatment of cyclosporin and SZC (treatment D) or vice versa.

    Drug: Cyclosporin · Drug: Sodium Zirconium Cyclosilicate

Interventions

  • Each subject in this cohort will receive a single dose of oral capsules of tacrolimus on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.

  • Each subject will receive a single dose of oral capsules of cyclosporin on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.

  • Each subject will receive single oral doses of SZC with tacrolimus (cohort 1) or cyclosporin (cohort 2) under fasted conditions. The doses will be administered after an overnight fast of at least 12 hours.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax)

    Effect of co-administered SZC on the Cmax of tacrolimus and cyclosporin in healthy participants was determined.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin

  2. Area Under Concentration-time Curve From Time Zero to Infinity (AUCinf)

    Effect of co-administered SZC on the AUCinf of tacrolimus and cyclosporin in healthy participants was determined.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin

Secondary outcomes

  1. Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)

    Effect of co-administered SZC on the AUClast of tacrolimus and cyclosporin in healthy participants was determined.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin

  2. Time to Reach Maximum Observed Concentration Following Drug Administration (Tmax)

    Effect of co-administered SZC on the tmax of tacrolimus and cyclosporin in healthy participants was determined.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin

  3. Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz)

    Effect of co-administered SZC on the t½λz of tacrolimus and cyclosporin in healthy participants was determined.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin

  4. Number of Participants With Adverse Events (AEs) and Serious AEs

    Safety and tolerability of co-administration of SZC and tacrolimus/cyclosporin as compared to tacrolimus/cyclosporin alone was assessed.

    Time frame: From the time of IMP administration (Day 1) to Follow-up/Early Termination Visit (7-10 days after last IMP administration) [up to 4 weeks]

07

Results

Posted Apr 5, 2024

Participant flow

The study was conducted at a single study centre (Berlin, Germany) between 30 March 2021 to 16 September 2021.

Treatment Period 1 (4 Days)
Participant flow — Treatment Period 1 (4 Days)
MilestoneCohort 1 (Tacrolimus): Treatment A, Then Treatment BCohort 1 (Tacrolimus): Treatment B, Then Treatment ACohort 2 (Cyclosporin): Treatment C, Then Treatment DCohort 2 (Cyclosporin): Treatment D, Then Treatment C
Started16151615
Completed16151615
Not completed0000
Washout Period (14 Days)
Participant flow — Washout Period (14 Days)
MilestoneCohort 1 (Tacrolimus): Treatment A, Then Treatment BCohort 1 (Tacrolimus): Treatment B, Then Treatment ACohort 2 (Cyclosporin): Treatment C, Then Treatment DCohort 2 (Cyclosporin): Treatment D, Then Treatment C
Started16151615
Completed16151615
Not completed0000
Treatment Period 2 (4 Days)
Participant flow — Treatment Period 2 (4 Days)
MilestoneCohort 1 (Tacrolimus): Treatment A, Then Treatment BCohort 1 (Tacrolimus): Treatment B, Then Treatment ACohort 2 (Cyclosporin): Treatment C, Then Treatment DCohort 2 (Cyclosporin): Treatment D, Then Treatment C
Started16151615
Completed15151415
Not completed1020
Withdrew: Protocol violation0010
Withdrew: Participant decided to discontinue further participation1000
Withdrew: Adverse event0010

Outcome measures

PrimaryMaximum Observed Concentration (Cmax)

Effect of co-administered SZC on the Cmax of tacrolimus and cyclosporin in healthy participants was determined.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Reported as:
Geometric mean · Picogram/milliliter (pg/ml)
Maximum Observed Concentration (Cmax)
Picogram/milliliter (pg/ml)Treatment A: Tacrolimus (5 mg)Treatment B: Tacrolimus (5 mg) and SZC (15 g)Treatment C: Cyclosporin (100 mg)Treatment D: Cyclosporin (100 mg) and SZC (15 g)
Maximum Observed Concentration (Cmax)27140 ± 37.6119350 ± 35.88593.6 ± 19.54608.1 ± 25.28
Statistical analysis
  • Treatment A: Tacrolimus (5 mg) vs Treatment B: Tacrolimus (5 mg) and SZC (15 g) · Geometric ls mean ratio (%): 71.10 · 90% CI 65.44 to 77.24Result based on a mixed effect following a natural logarithmic transformation of the individual PK parameters, with period, treatment, and sequence as fixed effects, and participant nested within sequence as random effects.
  • Treatment C: Cyclosporin (100 mg) vs Treatment D: Cyclosporin (100 mg) and SZC (15 g) · Geometric ls mean ratio (%): 102.9 · 90% CI 96.11 to 110.1Result based on a mixed effect following a natural logarithmic transformation of the individual PK parameters, with period, treatment, and sequence as fixed effects, and participant nested within sequence as random effects.
PrimaryArea Under Concentration-time Curve From Time Zero to Infinity (AUCinf)

Effect of co-administered SZC on the AUCinf of tacrolimus and cyclosporin in healthy participants was determined.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Reported as:
Geometric mean · Picogram.hour/milliliter
Area Under Concentration-time Curve From Time Zero to Infinity (AUCinf)
Picogram.hour/milliliterTreatment A: Tacrolimus (5 mg)Treatment B: Tacrolimus (5 mg) and SZC (15 g)Treatment C: Cyclosporin (100 mg)Treatment D: Cyclosporin (100 mg) and SZC (15 g)
Area Under Concentration-time Curve From Time Zero to Infinity (AUCinf)267900 ± 50.20171700 ± 48.951884 ± 25.901810 ± 23.91
Statistical analysis
  • Treatment A: Tacrolimus (5 mg) vs Treatment B: Tacrolimus (5 mg) and SZC (15 g) · Geometric ls mean ratio (%): 62.91 · 90% CI 55.64 to 71.13Result based on a mixed effect following a natural logarithmic transformation of the individual PK parameters, with period, treatment, and sequence as fixed effects, and participant nested within sequence as random effects.
  • Treatment C: Cyclosporin (100 mg) vs Treatment D: Cyclosporin (100 mg) and SZC (15 g) · Geometric ls mean ratio (%): 97.23 · 90% CI 92.93 to 101.7Result based on a mixed effect following a natural logarithmic transformation of the individual PK parameters, with period, treatment, and sequence as fixed effects, and participant nested within sequence as random effects.
SecondaryArea Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)

Effect of co-administered SZC on the AUClast of tacrolimus and cyclosporin in healthy participants was determined.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Reported as:
Geometric mean · Picogram.hour/milliliter
Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)
Picogram.hour/milliliterTreatment A: Tacrolimus (5 mg)Treatment B: Tacrolimus (5 mg) and SZC (15 g)Treatment C: Cyclosporin (100 mg)Treatment D: Cyclosporin (100 mg) and SZC (15 g)
Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast)240800 ± 50.79159000 ± 51.131792 ± 26.461718 ± 24.39
Statistical analysis
  • Treatment A: Tacrolimus (5 mg) vs Treatment B: Tacrolimus (5 mg) and SZC (15 g) · Geometric ls mean ratio (%): 65.57 · 90% CI 58.69 to 73.24Result based on a mixed effect following a natural logarithmic transformation of the individual PK parameters, with period, treatment, and sequence as fixed effects, and participant nested within sequence as random effects.
  • Treatment C: Cyclosporin (100 mg) vs Treatment D: Cyclosporin (100 mg) and SZC (15 g) · Geometric ls mean ratio (%): 97.04 · 90% CI 92.70 to 101.6Result based on a mixed effect following a natural logarithmic transformation of the individual PK parameters, with period, treatment, and sequence as fixed effects, and participant nested within sequence as random effects.
SecondaryTime to Reach Maximum Observed Concentration Following Drug Administration (Tmax)

Effect of co-administered SZC on the tmax of tacrolimus and cyclosporin in healthy participants was determined.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Reported as:
Median · hour
Time to Reach Maximum Observed Concentration Following Drug Administration (Tmax)
hourTreatment A: Tacrolimus (5 mg)Treatment B: Tacrolimus (5 mg) and SZC (15 g)Treatment C: Cyclosporin (100 mg)Treatment D: Cyclosporin (100 mg) and SZC (15 g)
Time to Reach Maximum Observed Concentration Following Drug Administration (Tmax)1.75 (1.00 to 3.00)1.50 (0.75 to 3.00)1.50 (0.75 to 2.50)1.25 (0.98 to 2.52)
Statistical analysis
  • Treatment A: Tacrolimus (5 mg) vs Treatment B: Tacrolimus (5 mg) and SZC (15 g) · Geometric ls mean ratio (%): 83.86 · 90% CI 73.38 to 95.84Result based on a mixed effect following a natural logarithmic transformation of the individual PK parameters, with period, treatment, and sequence as fixed effects, and participant nested within sequence as random effects.
  • Treatment C: Cyclosporin (100 mg) vs Treatment D: Cyclosporin (100 mg) and SZC (15 g) · Geometric ls mean ratio (%): 97.55 · 90% CI 87.16 to 109.2Result based on a mixed effect following a natural logarithmic transformation of the individual PK parameters, with period, treatment, and sequence as fixed effects, and participant nested within sequence as random effects.
SecondaryHalf-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz)

Effect of co-administered SZC on the t½λz of tacrolimus and cyclosporin in healthy participants was determined.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Reported as:
Geometric mean · hour
Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz)
hourTreatment A: Tacrolimus (5 mg)Treatment B: Tacrolimus (5 mg) and SZC (15 g)Treatment C: Cyclosporin (100 mg)Treatment D: Cyclosporin (100 mg) and SZC (15 g)
Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t½λz)33.59 ± 18.7233.31 ± 22.279.223 ± 32.788.647 ± 31.12
Statistical analysis
  • Treatment A: Tacrolimus (5 mg) vs Treatment B: Tacrolimus (5 mg) and SZC (15 g) · Geometric ls mean ratio (%): 98.42 · 90% CI 94.62 to 102.4Result based on a mixed effect following a natural logarithmic transformation of the individual PK parameters, with period, treatment, and sequence as fixed effects, and participant nested within sequence as random effects.
  • Treatment C: Cyclosporin (100 mg) vs Treatment D: Cyclosporin (100 mg) and SZC (15 g) · Geometric ls mean ratio (%): 94.12 · 90% CI 85.74 to 103.3Result based on a mixed effect following a natural logarithmic transformation of the individual PK parameters, with period, treatment, and sequence as fixed effects, and participant nested within sequence as random effects.
SecondaryNumber of Participants With Adverse Events (AEs) and Serious AEs

Safety and tolerability of co-administration of SZC and tacrolimus/cyclosporin as compared to tacrolimus/cyclosporin alone was assessed.

Time frame:
From the time of IMP administration (Day 1) to Follow-up/Early Termination Visit (7-10 days after last IMP administration) [up to 4 weeks]
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious AEs
ParticipantsTreatment A: Tacrolimus (5 mg)Treatment B: Tacrolimus (5 mg) and SZC (15 g)Treatment C: Cyclosporin (100 mg)Treatment D: Cyclosporin (100 mg) and SZC (15 g)
Any AE71387
Any AE with outcome = death0000
Any SAE (including events with outcome = death)0000
Any AE leading to discontinuation of IMP0010
Any AE leading to withdrawal from study0010

Adverse events

Collected over From the time of IMP administration (Day 1) to Follow-up/Early Termination Visit (7-10 days after last IMP administration) [up to 4 weeks]. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: Tacrolimus (5 mg)0/31 (0%)0/31 (0%)7/31 (22.6%)
Treatment B: Tacrolimus (5 mg) and SZC (15 g)0/30 (0%)0/30 (0%)13/30 (43.3%)
Treatment C: Cyclosporin (100 mg)0/31 (0%)0/31 (0%)8/31 (25.8%)
Treatment D: Cyclosporin (100 mg) and SZC (15 g)0/29 (0%)0/29 (0%)7/29 (24.1%)
Most frequent other events
Showing 10 of 29
Most frequent other events
EventTreatment A: Tacrolimus (5 mg)Treatment B: Tacrolimus (5 mg) and SZC (15 g)Treatment C: Cyclosporin (100 mg)Treatment D: Cyclosporin (100 mg) and SZC (15 g)
HeadacheNervous system disorders3/314/301/312/29
DysphagiaGastrointestinal disorders0/310/300/311/29
HaematocheziaGastrointestinal disorders0/310/301/311/29
Back painMusculoskeletal and connective tissue disorders0/310/300/311/29
Pain in extremityMusculoskeletal and connective tissue disorders1/310/300/311/29
Catheter site painGeneral disorders0/310/300/311/29
FatigueGeneral disorders0/310/300/311/29
Ligament sprainInjury, poisoning and procedural complications0/310/300/311/29
NasopharyngitisInfections and infestations0/311/301/310/29
RhinitisInfections and infestations0/311/300/310/29

Baseline characteristics

The randomised set consisted of all participants randomised into the study.

Age, Continuous
Age, Continuous(years)Cohort 1 (Tacrolimus): Treatment A, Then Treatment BCohort 1 (Tacrolimus): Treatment B, Then Treatment ACohort 2 (Cyclosporin): Treatment C, Then Treatment DCohort 2 (Cyclosporin): Treatment D, Then Treatment CTotal
Cohort 1 (Tacrolimus)38.3 ± 8.937.1 ± 9.6——37.7 ± 9.1
Cohort 2 (Cyclosporin)——33.2 ± 9.030.9 ± 8.332.1 ± 8.6
Age, Customized
Age, Customized(Participants)Cohort 1 (Tacrolimus): Treatment A, Then Treatment BCohort 1 (Tacrolimus): Treatment B, Then Treatment ACohort 2 (Cyclosporin): Treatment C, Then Treatment DCohort 2 (Cyclosporin): Treatment D, Then Treatment CTotal
18 - 50 years1615161562
51 years and older00000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (Tacrolimus): Treatment A, Then Treatment BCohort 1 (Tacrolimus): Treatment B, Then Treatment ACohort 2 (Cyclosporin): Treatment C, Then Treatment DCohort 2 (Cyclosporin): Treatment D, Then Treatment CTotal
Female12003
Male1513161559
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 (Tacrolimus): Treatment A, Then Treatment BCohort 1 (Tacrolimus): Treatment B, Then Treatment ACohort 2 (Cyclosporin): Treatment C, Then Treatment DCohort 2 (Cyclosporin): Treatment D, Then Treatment CTotal
White1415121354
Black or African American00202
Asian10113
Native Hawaiian or Other Pacific Islander00000
American Indian or Alaska Native00101
Other10012
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 (Tacrolimus): Treatment A, Then Treatment BCohort 1 (Tacrolimus): Treatment B, Then Treatment ACohort 2 (Cyclosporin): Treatment C, Then Treatment DCohort 2 (Cyclosporin): Treatment D, Then Treatment CTotal
Hispanic or Latino00101
Not Hispanic or Latino1615151561
08

Study locations

1 site
  • Research Site
    Berlin, 14050, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Sep 2021, 5 months.

Results were first posted in Apr 2024, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2021
First posted
Mar 9, 2021
StartActual
Mar 30, 2021
Primary completionActual
Sep 16, 2021
CompletionActual
Sep 16, 2021
Results first posted
Apr 5, 2024
Last update
Apr 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04788641
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Mar 9, 2021
Start date
Mar 30, 2021
Primary completion
Sep 16, 2021
Completion
Sep 16, 2021
Results posted
Apr 5, 2024
Last update
Apr 5, 2024

Study contacts

Thomas Koernicke, Dr
principal investigator · Parexel Early Phase Clinical Unit Berlin

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tacrolimus · Cyclosporine · Sodium zirconium cyclosilicate

Start the discussion